The acquisition adds a preclinical protein degrader program targeting acute myeloid leukemia to Amgen's oncology pipeline.

AI, compound interest—and friends in high places—have made these companies billionaire factories. In January 2025, as it was ...

Financial literacy is so much more than sticking to a budget and saving money. It’s understanding loans and credit cards and ...

The U.S. economy posted a 4.3% annualized real GDP growth rate in Q3 2025, the highest in two years. Read more about the US ...

The cryptocurrency market has recently experienced significantly increased volatility. Prices of popular digital assets ...

Cybersecurity failures aren’t about tools, they’re about people. ORCS turns risk awareness into everyday habits that help ...

Oregon’s first-in-the-nation retirement system is doing well. But people keep taking savings out before retirement.

The quest for a retirement-worthy cryptocurrency investment extends beyond mere price speculation. It requires an asse ...

NYU Professor of Business Vasant Dhar is a pioneer in the field of artificial intelligence. He's the host of the "Brave New ...

Hims & Hers Health, Inc. analysis: subscription health platform growth, GLP-1 risks, and catalysts in women’s health & ...

At the end of 2024, the Azores stood as a beacon of hope and a global leader in ocean conservation, having created the ...

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in ...